CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)	3 Months Ended		6 Months Ended
	Mar. 31, 2023	Mar. 31, 2022	Mar. 31, 2023	Mar. 31, 2022
Revenues
Total revenues	$ 4,407,614	$ 6,147,283	$ 9,670,366	$ 10,312,989
Total cost of revenues	2,600,179	3,658,798	5,485,248	6,715,366
Gross profit	1,807,435	2,488,485	4,185,118	3,597,623
Operating expenses:
Selling, general and administrative	3,522,715	3,572,680	6,148,072	8,308,299
Research and development	988,744	1,070,041	1,960,048	2,150,137
Total operating expenses	4,511,459	4,642,721	8,108,120	10,458,436
LOSS FROM OPERATIONS	(2,704,024)	(2,154,236)	(3,923,002)	(6,860,813)
Interest income	3,639	5,540	7,325	5,813
Transaction cost allocated to warrant liabilities	0	(391,335)		(391,335)
Unrealized gain on change in fair value of warrants classified as a liability	3,250,900	782,500	613,100	782,500
Other income (expense), net	661	(2,266)	9,507	(16,873)
Income (loss) before provision for income taxes	551,176	(1,759,797)	(3,293,070)	(6,480,708)
Provision for income taxes	0	0	0	0
NET INCOME (LOSS)	551,176	(1,759,797)	(3,293,070)	(6,480,708)
Less: Net loss attributable to noncontrolling interest	37,167	1,112	38,041	257
NET INCOME (LOSS) attributable to Applied DNA Sciences, Inc.	588,343	(1,758,685)	(3,255,029)	(6,480,451)
Deemed dividend related to warrant modification	0	110,105		110,105
NET INCOME (LOSS) attributable to common stockholders	$ 588,343	$ (1,868,790)	$ (3,255,029)	$ (6,590,556)
Net income (loss) per share attributable to common stockholders-basic	$ 0.05	$ (0.23)	$ (0.25)	$ (0.85)
Net income (loss) per share attributable to common stockholders- diluted	$ 0.05	$ (0.23)	$ (0.25)	$ (0.85)
Weighted average shares outstanding - basic	12,908,520	8,084,680	12,908,520	7,783,747
Weighted average shares outstanding - diluted	12,908,520	8,084,680	12,908,520	7,783,747
Product revenues
Revenues
Total revenues	$ 297,454	$ 408,351	$ 813,850	$ 1,234,662
Total cost of revenues	369,563	469,981	734,941	904,910
Service revenues
Revenues
Total revenues	169,058	248,690	401,119	387,963
Clinical laboratory service revenues
Revenues
Total revenues	3,941,102	5,490,242	8,455,397	8,690,364
Total cost of revenues	$ 2,230,616	$ 3,188,817	$ 4,750,307	$ 5,810,456